Literature DB >> 22593500

Infiltration of colorectal carcinoma by S100+ dendritic cells and CD57+ lymphocytes as independent prognostic factors after radical surgical treatment.

Vaclav Liska1, Ondrej Vycital, Ondrej Daum, Petr Novak, Vladislav Treska, Jan Bruha, Pavel Pitule, Lubos Holubec.   

Abstract

BACKGROUND: S100(+) dendritic cells and CD57(+) lymphocytes are factors reflecting the immune system's ability to suppress the progress of tumor growth. CD57(+) cells include natural killer cells and late stages of T-effector lymphocytes. We evaluated the relationship between the known clinical and histological factors and tumor markers as well as the presence of S100(+) and CD57(+) cells in the tissue of colorectal carcinoma with the aim of detecting patients at high risk of short overall survival (OS) or short disease-free interval (DFI) after radical surgical treatment and we further analyzed whether S100(+) and CD57(+) positivity could bring on new information regarding the treatment regimen.
MATERIALS AND METHODS: Data of 150 patients (97 males and 53 females) that underwent an elective radical surgical procedure for colorectal cancer were studied. The influence on DFI and on OS of the following parameters was evaluated: grading, staging and positivity for S100 and CD57 by immunohistochemical staining. We also analyzed the relation of preoperative serum levels of the tumor markers Carcinoembryonic Antigen (CEA), Cancer Antigen 19-9 (CA19-9), Cancer Antigen 72-4 (CA72-4), Thymidine kinase (TK), Tissue-Specific Polypeptide Antigen (TPS) and Tissue Polypeptide Antigen (TPA) in relation to S100 and CD57 positivity/negativity for the same patients.
RESULTS: OS at 1, 3 and 5 years was 92.2%, 76.5% and 70.2%; the DFI at 1, 3 and 5 years was 85.3%, 64.3% and 49.4%. CD57 positivity in the tumor mass was proven as a positive prognostic factor for OS. Risk of short OS was 2.5-fold higher in patients with low tumor infiltration by CD57(+) lymphocytes. The combination of N2 stage for lymph nodes and the absence of CD57(+) cells was proven to be the strongest negative prognostic factor for OS. No significant influence of CD57 positivity on DFI appeared. There was no significant influence of S100 positivity on OS or DFI; nor was there any statistical dependence of CD57 and S100 positivity or negativity on preoperative serum levels of CEA, CA19-9, CA72-4, TK, TPS or TPA. Both studied factors were shown to be statistically independent factors.
CONCLUSION: The present study showed infiltration of colorectal cancer tissue by CD57(+) cells as being an important independent positive prognostic factor for OS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593500

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.

Authors:  Pavel Pitule; Miroslava Cedikova; Ondrej Daum; Jan Vojtisek; Ondrej Vycital; Petr Hosek; Vladislav Treska; Ondrej Hes; Milena Kralickova; Vaclav Liska
Journal:  Biomed Res Int       Date:  2014-04-22       Impact factor: 3.411

2.  Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis.

Authors:  Shuo Zhang; Weijian Liu; Binwu Hu; Peng Wang; Xiao Lv; Songfeng Chen; Zengwu Shao
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

3.  S100 expression in dendritic cells is inversely correlated with tumor grade in endometrial carcinoma.

Authors:  Young Joo Lee; Sun Young Kang; Moo Sung Jo; Dong Soo Suh; Ki Hyung Kim; Man Soo Yoon
Journal:  Obstet Gynecol Sci       Date:  2014-05-15

4.  Evaluation of natural killer cell (CD57) as a prognostic marker in oral squamous cell carcinoma: An immunohistochemistry study.

Authors:  Rashmi Agarwal; Minal Chaudhary; Shruti Bohra; Shree Bajaj
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

5.  Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: a meta-analysis.

Authors:  Guoming Hu; Shimin Wang
Journal:  Oncotarget       Date:  2017-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.